NEW YORK and MELBOURNE, Australia, June 18, 2025 (GLOBE NEWSWIRE) -- Incannex Healthcare Inc. (Nasdaq: IXHL) (“Incannex” or the “Company”), a clinical-stage biopharmaceutical company advancing ...
Phase 2 trial data will continue to be the name of the game when it comes to VC investments into biopharma in 2025, according to PitchBook. “In 2025, venture capitalists are expected to prioritize ...
Stocktwits on MSN
Why did RVPH stock crash 50% today?
FDA recommended that Reviva conduct a second Phase 3 clinical trial to generate additional efficacy data and expand ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback